1. Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer 
Usman Ahmad, MD, Traves D. Crabtree, MD, Aalok P. Patel, BS, Daniel Morgensztern, MD, Cliff G. Robinson, MD, A. Sasha Krupnick, MD, Daniel Kreisel, MD, PhD, David R. Jones, MD, G. Alexander Patterson, MD, Bryan F. Meyers, MD, MPH, Varun Puri, MD, MSCI 
The Annals of Thoracic Surgery 
Volume 104, Issue 1, Pages (July 2017)
DOI: /j.athoracsur
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

2. Fig 1
Overall survival (OS) in patients with non-small cell lung cancer (NSCLC) who underwent lobectomy with chest wall resection with or without adjuvant chemotherapy (chemo). N = 824, no chemo = 569, adjuvant chemo = 255. Median OS 19 versus 36 months, p < (Cum = cumulative; Dx = diagnosis.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

3. Fig 2
Overall survival (OS) in patients with non-small cell lung cancer (NSCLC) who underwent lobectomy with chest wall resection with complete or incomplete resection. N = 806, complete resection = 705, incomplete resection = 101. Median OS 27 versus 13 months, p < (Cum = cumulative; Dx = diagnosis.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions